James Heath,
Elizabeth W. Gilloon Professor of Chemistry,
California Institute of Technology (CalTech)
Jim Heath is the Elizabeth Gilloon Professor and Professor of Chemistry at Caltech, and Professor of Molecular and Medical Pharmacology at UCLA. He directs the National Cancer Institute funded NSB Cancer Center. He received his Ph.D. in 1988 from Rice University where he was the principle graduate student involved in the discovery of C60 and the fullerenes. He was a Miller Fellow at UC Berkeley before joining the research staff at IBM Watson Labs in 1991. He took a faculty position at UCLA in 1994, and moved to Caltech in 2003. He has received the Irving Weinstein Award from the AACR and the Sackler Prize in the Physical Sciences. He was named by Forbes in 2009 as one of the top 7 innovators in the world.
Technologies for Personalizing Cancer Immunotherapies
Monday, 26 September 2016 at 17:30
Add to Calendar ▼2016-09-26 17:30:002016-09-26 18:30:00Europe/LondonTechnologies for Personalizing Cancer ImmunotherapiesNGS, SCA, SMA and Mass Spec: Research to Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Cancer immunotherapy, which has taken virtually all aspects of oncology by storm over the past few years, is based upon using cellular or molecular therapies to promote tumor cell/immune cell interactions. At the heart of this therapy are the T cells that actually do the tumor cell killing, and the tumor antigens that are recognized by those T cells. Recent work has shown that neoantigens play critical roles in many immunotherapy successes. Neoantigens are tumor antigens that are fragments of mutated proteins expressed by the cancer cells, and contain those point mutations. They are presented in the clefts of major histocompatibility molecules (MHCs) by many of the cells in the tumor, where they may be recognized by neoantigen-specific T cell populations. In this presentation, I will discuss how various micro and nanotechnologies are being harnessed to identify, for a given patient which neoantigens are actively recruiting T cells into the tumor, and to carry out a deep molecular analysis of those neoantigen-specific T cells. I will further discuss how that information can then be harnessed for personalized cancer immunotherapies in the form of neoantigen-based vaccines, or engineered T cell receptor adoptive cell transfer therapies.
Add to Calendar ▼2016-09-26 00:00:002016-09-28 00:00:00Europe/LondonNGS, SCA, SMA and Mass Spec: Research to Diagnostics 2016NGS, SCA, SMA and Mass Spec: Research to Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-09-26 17:30:002016-09-26 18:30:00Europe/LondonTechnologies for Personalizing Cancer ImmunotherapiesNGS, SCA, SMA and Mass Spec: Research to Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
